C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Other Liabilities
AU$1.1m
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
26%
R
Respiri Ltd
ASX:RSH
Other Liabilities
AU$70.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ImpediMed Ltd
ASX:IPD
Other Liabilities
AU$776k
CAGR 3-Years
25%
CAGR 5-Years
42%
CAGR 10-Years
24%
Cochlear Ltd
ASX:COH
Other Liabilities
AU$52.1m
CAGR 3-Years
1%
CAGR 5-Years
-14%
CAGR 10-Years
-1%
Optiscan Imaging Ltd
ASX:OIL
Other Liabilities
AU$7.9k
CAGR 3-Years
-8%
CAGR 5-Years
29%
CAGR 10-Years
-9%
EMvision Medical Devices Ltd
ASX:EMV
Other Liabilities
AU$72.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
167.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Other Liabilities?
Other Liabilities
1.1m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Other Liabilities amounts to 1.1m AUD.

What is Cyclopharm Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
26%

Over the last year, the Other Liabilities growth was 18%. The average annual Other Liabilities growth rates for Cyclopharm Ltd have been 5% over the past three years , 11% over the past five years , and 26% over the past ten years .

Back to Top